⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030: Rapid Adoption of Targeted Therapies and Immunotherapy Fuels Market Expansion, Reaching $70.8 Billion by 2030
globenewswire.com
PFE
MRK
ABBV
NVS
SNY
BMY
AZN
GSK
Esophageal Cancer Market to Grow from $1.65 Billion in 2026 to $2.37 Billion by 2030: Pfizer, Roche, Merck & Co. Dominate
globenewswire.com
PFE
MRK
NVS
PRPH
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
globenewswire.com
NVS
Институт Critical Path Institute запускает программу One to Millions, чтобы изменить будущее персонализированной медицины в глобальном масштабе USA - Pусский USA - English USA - English USA - Français USA - slovenčina USA - Polski USA - español USA -
prnewswire.com
BMY
MRK
PFE
GILD
REGN
AZN
NVS
BIIB
ALKS
CRIS
EDIT
NTLA
Pelvic Cancer Induced Hemorrhagic Cystitis Market Poised for Very Strong Growth: Expected to Reach $7.98 Billion by 2030
globenewswire.com
PFE
JNJ
MRK
ABBV
SNY
BMY
AZN
NVS
AMGN
Vulvar Cancer Market Size to Grow by $270 Million During 2026-2030: Investments and Personalized Medicine Drive Market Expansion
globenewswire.com
MRK
BMY
NVS
CAR T-Cell Therapy Market to Hit USD 13.78 Billion by 2031, Driven by Rising Global Cancer Prevalence - Insights by Product, Target, Indication, Demographic, Region, and Competitive Landscape
globenewswire.com
BIIB
GILD
BMY
NVS
MRK
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
globenewswire.com
NVS
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
globenewswire.com
NVS
Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
globenewswire.com
ABBV
AZN
BIIB
BMY
GSK
LLY
MRK
NVS
SNY
TEVA
UCB